Thus, vaccines produced by a combination of HDAC plus DNMT inhibition could be an approach for pancreatic cancer interception, increasing MHC-II expression and triggering an anti-tumoral immune response. This evidence concerns the gene HDAC9 and pancreatic neoplasm.